195 related articles for article (PubMed ID: 29425766)
21. SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model.
Tahara A; Takasu T
Physiol Rep; 2019 Nov; 7(22):e14286. PubMed ID: 31782258
[TBL] [Abstract][Full Text] [Related]
22. Protective Effect of Ipragliflozin on Pancreatic Islet Cells in Obese Type 2 Diabetic db/db Mice.
Takasu T; Takakura S
Biol Pharm Bull; 2018; 41(5):761-769. PubMed ID: 29709913
[TBL] [Abstract][Full Text] [Related]
23. Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus.
Schwartz SL; Akinlade B; Klasen S; Kowalski D; Zhang W; Wilpshaar W
Diabetes Technol Ther; 2011 Dec; 13(12):1219-27. PubMed ID: 21854192
[TBL] [Abstract][Full Text] [Related]
24. Time-dependent effects of ipragliflozin on behaviour and energy homeostasis in normal and type 2 diabetic rats: continuous glucose telemetry analysis.
Iuchi H; Sakamoto M; Matsutani D; Suzuki H; Kayama Y; Takeda N; Minamisawa S; Utsunomiya K
Sci Rep; 2017 Sep; 7(1):11906. PubMed ID: 28928461
[TBL] [Abstract][Full Text] [Related]
25. Sodium-Glucose Cotransporter 2 Inhibitor and a Low Carbohydrate Diet Affect Gluconeogenesis and Glycogen Content Differently in the Kidney and the Liver of Non-Diabetic Mice.
Atageldiyeva K; Fujita Y; Yanagimachi T; Mizumoto K; Takeda Y; Honjo J; Takiyama Y; Abiko A; Makino Y; Haneda M
PLoS One; 2016; 11(6):e0157672. PubMed ID: 27327650
[TBL] [Abstract][Full Text] [Related]
26. Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention in type 2 diabetic mice with NASH.
Tahara A
Eur J Pharmacol; 2021 Jun; 901():174076. PubMed ID: 33798599
[TBL] [Abstract][Full Text] [Related]
27. Effect of ipragliflozin, an SGLT2 inhibitor, on cardiac histopathological changes in a non-diabetic rat model of cardiomyopathy.
Takasu T; Takakura S
Life Sci; 2019 Aug; 230():19-27. PubMed ID: 31125563
[TBL] [Abstract][Full Text] [Related]
28. Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin.
Kadokura T; Zhang W; Krauwinkel W; Leeflang S; Keirns J; Taniuchi Y; Nakajo I; Smulders R
Clin Pharmacokinet; 2014 Nov; 53(11):975-88. PubMed ID: 25316572
[TBL] [Abstract][Full Text] [Related]
29. Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
Imamura M; Nakanishi K; Suzuki T; Ikegai K; Shiraki R; Ogiyama T; Murakami T; Kurosaki E; Noda A; Kobayashi Y; Yokota M; Koide T; Kosakai K; Ohkura Y; Takeuchi M; Tomiyama H; Ohta M
Bioorg Med Chem; 2012 May; 20(10):3263-79. PubMed ID: 22507206
[TBL] [Abstract][Full Text] [Related]
30. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.
Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
J Pharmacol Sci; 2016 Mar; 130(3):159-69. PubMed ID: 26970780
[TBL] [Abstract][Full Text] [Related]
31. Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages.
Koike M; Saito H; Kohno G; Takubo M; Watanabe K; Ishihara H
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768897
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic and pharmacodynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study.
Kadokura T; Akiyama N; Kashiwagi A; Utsuno A; Kazuta K; Yoshida S; Nagase I; Smulders R; Kageyama S
Diabetes Res Clin Pract; 2014 Oct; 106(1):50-6. PubMed ID: 25149596
[TBL] [Abstract][Full Text] [Related]
33. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.
Gembardt F; Bartaun C; Jarzebska N; Mayoux E; Todorov VT; Hohenstein B; Hugo C
Am J Physiol Renal Physiol; 2014 Aug; 307(3):F317-25. PubMed ID: 24944269
[TBL] [Abstract][Full Text] [Related]
34. Atypical Ketoacidosis and Protracted Hyperglycosuria after Treatment with Ipragliflozin, an SGLT2 Inhibitor.
Miyauchi M; Toyoda M; Fukagawa M
Intern Med; 2017; 56(13):1673-1678. PubMed ID: 28674356
[TBL] [Abstract][Full Text] [Related]
35. Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects.
Veltkamp SA; Kadokura T; Krauwinkel WJ; Smulders RA
Clin Drug Investig; 2011 Dec; 31(12):839-51. PubMed ID: 21877761
[TBL] [Abstract][Full Text] [Related]
36. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats.
Nishimura N; Kitade M; Noguchi R; Namisaki T; Moriya K; Takeda K; Okura Y; Aihara Y; Douhara A; Kawaratani H; Asada K; Yoshiji H
J Gastroenterol; 2016 Dec; 51(12):1141-1149. PubMed ID: 27025708
[TBL] [Abstract][Full Text] [Related]
37. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
Veltkamp SA; van Dijk J; Collins C; van Bruijnsvoort M; Kadokura T; Smulders RA
Clin Ther; 2012 Aug; 34(8):1761-71. PubMed ID: 22795925
[TBL] [Abstract][Full Text] [Related]
38. In Vitro Pharmacological Profile of Ipragliflozin, a Sodium Glucose Co-transporter 2 Inhibitor.
Takasu T; Yokono M; Tahara A; Takakura S
Biol Pharm Bull; 2019; 42(3):507-511. PubMed ID: 30828082
[TBL] [Abstract][Full Text] [Related]
39. Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice.
Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
Eur J Pharmacol; 2017 Aug; 809():163-171. PubMed ID: 28506912
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium-glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus.
Saito M; Kaibara A; Kadokura T; Toyoshima J; Yoshida S; Kazuta K; Ueyama E
Br J Clin Pharmacol; 2019 Aug; 85(8):1808-1819. PubMed ID: 31026084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
